ZedScan™ Clinical Impact See and Treat/Select and Treat NHSCSP Colposcopy Standards* • PPV for colposcopic diagnosis of HG-CIN should be ≥65%. • Treatment at first visit requires a PPV≥ 90% for HG-CIN. • Women with low grade dyskaryosis should not be managed on a See and Treat basis to avoid over-treatment. • 100% of women having definitive treatment for high grade CIN must be treated within 8 weeks. Comparison of Colposcopy Vs ZedScan™ + Colposcopy for all patient referrals 1 Key to ROC Curve = ZedScan™ + Colposcopy Sensitivity (True Positives) 0.8 0.7 0.6 Single Biopsy Needed 0.5 Improved Sensitivity and Specificity ZedScan™ enables clinicians to meet the NHS Cervical Screening Programme standards for See and Treat. Using ZedScan™ as an adjunct to colposcopy increases the accuracy of HG-CIN detection in high grade referrals. High Grade Referrals 100% • ensitivity 65% HG-CIN S • atients not identified for immediate treatment will P still be selected for biopsy with 92% sensitivity for detection of High Grade disease Colposcopy Only • pecificity 95% HG-CIN S • an achieve PPV of 97% – increasing confidence to C treat at first visit and reducing over-treatment • apid real-time results R • acilitates clinical decision at first visit F • eduction in deferred treatment appointments R releases clinic time for new appointments v1.0 04/13 www.zilico.co.uk 461h Zilico See & Treat Flyer.indd 1